Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 196

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 196
---
 more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since we failed to complete our initial business combination by December 6, 2024, Nasdaq’s staff concluded that the we did not comply with Rule IM -5101-2and that our securities are now subject to delisting. As a result, trading in our securities on Nasdaq was effectively suspended with the open of the market on December 17, 2024, and our securities are currently eligible to trade only on the over -the -countermarkets system. On March21, 2025, Nasdaq filed a Form 25 -NSEin respect of APx’s Class A ordinary shares with the SEC, and the delisting of APx’s Class A ordinary shares became effective on March31, 2025. On May8, 2025, Nasdaq filed a Form 25 -NSEin respect of APx’s units and warrants with the SEC, and the delisting of APx’s units and warrants will become effective on May18, 2025. Following the delisting on Nasdaq, APx’s Class A ordinary shares are quoted on the Pink Open Market of the OTC under the symbol “APXIF”. We will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information. Despite the delisting of our securities from Nasdaq, we intend to proceed with our efforts to consummate our initial Business Combination. However, Nasdaq approval of OmnigenicsAI’s initial listing application with respect to the Business Combination is a condition to such Business Combination, and there can be no guarantee that Nasdaq will approve such initial listing application, which may delay, or ultimately prevent the consummation of the proposed Business Combination. There can be no assurance that we will be able to satisfy Nasdaq’s initial listing requirements, or regain compliance with Nasdaq’s continued listing requirements, in a timely manner, or at all, and such delisting may delay, or ultimately prevent, the consummation of the Business Combination. In order to close the Business Combination, we will be required to demonstrate compliance with Nasdaq’s initial listing requirements, which are generally more rigorous than Nasdaq’s continued listing requirements. We believe that we will be able to evidence compliance with Nasdaq’s initial listing requirements (and therefore also necessarily regain compliance with respect to all applicable continued listing requirements) upon the consummation of the 77 Business Combination, with such